Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of June 2019, specifically dated June 3, 2019. The filing serves to incorporate by reference a press release regarding clinical trial data presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development updates rather than financial performance.
Material Changes
The material event reported is the presentation of data from a recently completed Phase II trial in patients with hepatocellular cancer. This data was presented as a late-breaking abstract at the ASCO annual meeting.
Guidance, Outlook, and Risks
The filing incorporates the "Forward Looking Statements" section of the attached press release by reference. No specific financial guidance, management commentary on operations, or detailed risk factors are provided within the body of this Form 6-K text.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release dated June 3, 2019) for specific clinical trial results and statistical data.
- Verify the incorporation of this press release into the company's Registration Statements on Form S-8 and Form F-3.
- Consult the company's most recent Form 20-F for the latest audited financial statements, as this filing contains no financial data.